The sector’s crisis communication challenge
A pharmaceutical company may need to explain a safety signal as the evaluation continues. Two symmetrical errors threaten trust: denying a concern too early or presenting an observed association as demonstrated causality. Crisis communication must make the status of knowledge visible. It must also take into account the risk that a patient changes their treatment on their own after reading an alarming headline.
The EMA includes risk communication in the monitoring of medicines. The reasoning proposed here concerns the way in which medical, regulatory and communications departments work together. Their responsibilities differ, but the public perceives only one company. A message must therefore be scientifically defensible and understandable without specialized training. [1]
Build the risk matrix
The matrix must distinguish a signal to be investigated, an identified quality defect and an availability difficulty. These situations have neither the same recipients nor the same consequences. A batch defect may require targeted information; a more diffuse signal requires specifying the scope of the evaluation. A break in availability calls for coordination on therapeutic continuity, which cannot be improvised through communication.
The level of evidence should appear in a separate column from the severity. A potentially significant but still uncertain risk may justify strong mobilization. Conversely, high-profile information may concern a limited area. The volume of mentions should not alone decide medical priority, even if it signals an urgent need for explanation.
Prepare decisions and public messages
The patient, the prescriber, the pharmacist and the investor are not looking for the same answer. Consistency does not mean broadcasting the same text to everyone. The contents must retain the same facts and the same reservations, while responding to different decisions. Documents intended for professionals must follow the validation and coordination processes applicable in the countries concerned.
The temptation to simplify the benefit-risk ratio through an advertising formula must be avoided. The context of use and the recognized uncertainties must be explained, without giving individual advice. When instructions are necessary, they must come from the relevant medical and regulatory approval process. Public relations teams must know how to direct a clinical question rather than attempt to answer it.
Test the response with a crisis simulation
In a hypothetical case, a published study provokes requests from patients, while its results do not allow an individual conclusion. The exercise tests the ability to quickly produce a medical note, an accessible response and a procedure for escalating questions. The simulation then introduces a translation which transforms an “association” into a “cause”. This seemingly minor modification can radically change the public meaning of the message.
The crisis management team must correct the affected version and verify the revisions. It keeps track of validations, schedules and people informed. The linguistic version cannot be a simple by-product of international communication: certain words carry a central scientific responsibility.
Verify recovery and learn from the incident
The assessment must measure unmet information needs, understanding of messages and the ability to update content when the evaluation evolves. An absence of questions does not establish absence of confusion. Field teams can identify persistent interpretations and transmit them to the decision-making process.
Good pharmaceutical communication agrees to remain provisional when knowledge is. Its credibility comes from the discipline which links each assertion to a status of proof, to an addressee and to responsibility. The risk matrix then serves to organize this discipline, rather than to create premature certainty.
Sector risk matrix — illustrative example
Hypothetical ratings over twelve months, not a measured company assessment. P × G supports prioritisation; an impact of 5 requires priority attention. Operational thresholds must be set by the competent teams. How to use the matrices
| Scenario | Likelihood | Impact | Score | Warning sign | Decision to prepare | Evidence required |
|---|---|---|---|---|---|---|
| Safety signal under evaluation | 3 | 5 | 15* | Signal deemed relevant by pharmacovigilance | Coordinate assessment and validated information | Medical note and knowledge status |
| Quality defect concerning a batch | 2 | 5 | 10* | Confirmation by quality | Define the scope with the competent managers | Batch traceability and formalized decisions |
| Translation transforming medical meaning | 3 | 4 | 12 | Deviation from causality or instruction | Correct and verify broadcast channels | Multilingual terminology validation |
Sector source
Sources accessed on 9 October 2026. Examples are hypothetical and do not describe client assignments.
Further reading
Cite this article
Belief System. Pharmaceuticals: explain a safety signal without creating a second crisis. . https://beliefsystem.fr/en/regards/pharma-safety-uncertainty/